REFERENCES
1. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia.Hematology Am Soc Hematol Educ Program. 2016;2016(1):580-588.
2. McMahon CM, Luger SM. Relapsed T Cell ALL: Current Approaches and New Directions. Curr Hematol Malig Rep. 2019;14(2):83-93.
3. Durinck K, Goossens S, Peirs S, et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol.2015;43(8):625-639.
4. Patrick K, Vora A. Update on biology and treatment of T-cell acute lymphoblastic leukaemia. Curr Opin Pediatr. 2015;27(1):44-49.
5. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A. 1980;77(3):1588-1592.
6. van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95-112.
7. Bride KL, Vincent TL, Im SY, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood.2018;131(9):995-999.
8. van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127(6):681-695.
9. Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. Cancer. 2019;125(14):2364-2382.
10. Vogiatzi F, Winterberg D, Lenk L, et al. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood. 2019;134(8):713-716.
11. Ofran Y, Ganzel C, Harlev S, et al. Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse. Blood.2018;132(Supplement 1):5206-5206.
12. Ofran Y, Ringelstein-Harlev S, Slouzkey I, et al. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia.2020;34(1):293-295.
13. Bethesda (MD): National Library of Medicine. ClinialTrials.gov. Identifier NCT03384654, A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Web site. https://clinicaltrials.gov/ct2/show/NCT03384654. Published 2017. Updated April 24 2020. Accessed 9 June, 2020.